Open an account

Edap Tms SA

FOCL · NASDAQ

$4.20+$0.13 (+3.19%)TodayMarket closed ·
Prev close $4.07

About FOCL

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 289 full-time employees. The firm's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. The company specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. The company also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

Employees
289
Headquarters
Vaulx-en-Velin, Auvergne-Rhone-Alpes
Listed
Aug 1, 1997
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
focalone.com

FOCL key statistics

Market cap
152.55M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
68.86K
Volume
11.11K
Open price
$4.14
High today
$4.26
Low today
$4.12
52 Week high
$6.40
52 Week low
$1.75

Edap Tms SA (FOCL) at a glance

As of Oct 20, 2026, Edap Tms SA (FOCL) shares are priced at $4.20, giving the company a market cap of 152.55M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.12 and $4.26. The current price is 2.0% above the day's low and 1.4% below its high.

Volume so far is 11.11K shares, below the average of 68.86K shares a day.

Over the past year Edap Tms SA has ranged from $1.75 to $6.40, and now sits 53% of the way up that range.

Edap Tms SA met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.3905 per share against an estimate of -$0.2316.

The average analyst price target is $8.98, 113.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $8.98
Low
$4.04
Now
$4.20
High
$15.75

FOCL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 33.2% on average.

  1. Q3 FY24: reported -$0.17 per share against an estimate of -$0.1487
  2. Q4 FY24: reported -$0.05 per share against an estimate of -$0.1017
  3. Q1 FY25: reported -$0.19 per share against an estimate of -$0.154
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.163
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.2199
  6. Q4 FY25: reported -$0.22 per share against an estimate of -$0.1301
  7. Q1 FY26: reported -$0.2399 per share against an estimate of -$0.2208
  8. Q2 FY26: reported -$0.3905 per share against an estimate of -$0.2316

FOCL news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.